Bronchoprotection of Salbutamol in Asthma and Chronic Obstructive Pulmonary Disease
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Bronchoprotection of Salbutamol in Asthma and COPD|
- methacholine PC20 dose shift [ Time Frame: one hour ]
|Study Start Date:||February 2007|
|Estimated Study Completion Date:||May 2017|
|Estimated Primary Completion Date:||May 2017 (Final data collection date for primary outcome measure)|
There are two groups, asthma and COPD, which are being compared with respect to bronchoprotection from an active treatment (salbutamol).
200 micrograms salbutamol from MDI
In asthma, the administration (inhalation) of a selective β2 receptor agonist (e.g. salbutamol), prior to methacholine challenge has been shown to shift the dose response curve to the right and "bronchoprotect" the airway against airway smooth muscle contraction. The extent of β2 receptor agonist bronchoprotection in COPD is unknown.
Airway hyperresponsiveness (AHR) to direct acting agents such as histamine and methacholine is a feature of both asthma and COPD. In asthma, the abnormality leading to AHR is believed to be due to changes in airway smooth muscle (e.g. hypertrophy, hyperplasia, contractile apparatus) whereas in COPD the AHR is likely due to structural or geometric changes.
The investigators hypothesize that the bronchoprotection afforded by salbutamol against methacholine challenge will be greater in asthma than in COPD due to differences in underlying airway abnormalities.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00440245
|Contact: Beth Davis, PhDfirstname.lastname@example.org|
|University of Saskatchewan||Recruiting|
|Saskatoon, Saskatchewan, Canada, S7N0W8|
|Contact: Beth Davis, PhD 306-844-1444 email@example.com|
|Principal Investigator: Donald Cockcroft, MD|
|Principal Investigator:||Donald Cockcroft, MD||University of Saskatchewan|